The federal government is moving toward unified AI regulation, and health care organizations face a critical window to shape how these rules will affect patient care, liability, and innovation. Two major developments signal that AI governance is shifting from theoretical debate to legislative reality: the Trump administration released its National Policy Framework for Artificial Intelligence in March 2026, and Senator Marsha Blackburn introduced the Trump America Act, comprehensive proposed legislation that would establish a single federal rulebook for AI governance .

For hospitals, clinics, and life sciences companies, the stakes are extraordinarily high. AI is already embedded throughout the health care system, from diagnostic imaging and clinical decision support to revenue cycle management, drug discovery, and clinical trial optimization. Both proposals would introduce new liability frameworks, mandatory bias audits, copyright-based training data requirements, and transparency obligations that directly affect these high-risk, data-intensive applications .

What Would These New AI Rules Actually Require of Health Care Organizations?

The Trump America Act proposes several provisions that would fundamentally reshape how health care AI systems operate. The most consequential changes include a new statutory duty of care requiring organizations to prevent and mitigate foreseeable harm from AI systems, federal private rights of action for defective design and failure to warn, and mandatory bias audits specifically for high-risk AI systems used in treatment recommendations, insurance eligibility decisions, or clinical resource allocation .

The bias audit requirement deserves particular attention because it differs from existing anti-discrimination frameworks. The proposed legislation would require audits to "detect any viewpoint discrimination or discrimination based on political affiliation," which is narrower than traditional anti-discrimination frameworks under Section 1557 of the Affordable Care Act that have been applied by the Department of Health and Human Services to clinical algorithms . This creates a potential compliance gap: organizations would need to satisfy both the new federal bias audit standard and existing HHS expectations for AI performance across demographic subgroups.

The Framework, released on March 20, 2026, organizes its legislative recommendations around seven core objectives. For health care, the most relevant are intellectual property protections including collective licensing frameworks, enabling innovation through regulatory sandboxes and sector-specific oversight, and federal preemption of state AI laws that impose "undue burdens" while preserving state police powers and state procurement requirements .

How Should Health Care Organizations Prepare for These Changes?

• Assess Liability Exposure: Organizations developing, deploying, or substantially modifying clinical AI systems should evaluate whether existing indemnification, quality management, and risk disclosure documentation is robust enough to defend against AI-related claims under a new products liability framework. Products liability theories are already being pursued in active litigation regardless of how the Act takes shape.
• Review Consent and Data Frameworks: The Act would incorporate the NO FAKES Act, establishing rights for individuals to control the use of their digital likeness. Organizations using patient images, voice recordings, or other biometric data in AI development should assess whether current consent frameworks would adequately address these digital replica rights if enacted.
• Maintain Multi-Jurisdictional Compliance Programs: While the Framework calls for broad federal preemption, the Act would preserve "generally applicable law" and "sectoral governance schemes." This means HIPAA, state health data privacy laws, and FDA authority over AI-enabled medical devices would remain intact. Organizations should maintain robust state compliance programs rather than assuming federal legislation will provide preemptive relief.
• Evaluate Section 230 Implications: The Act would sunset Section 230 of the Communications Act, which currently exempts platforms from liability for third-party content. Health information platforms, telehealth providers, and patient-facing AI tools that rely on current liability protections should evaluate how this proposed change would reshape their risk profiles.

A critical gap exists in both proposals: neither the Framework nor the Act directly addresses how federal AI policy would interact with the FDA's authority over AI-enabled medical devices. This is a significant oversight that health care and life sciences stakeholders should work to fill through legislative engagement .

The distinction between the Framework and the Act matters considerably for health care organizations. The Framework calls for broad preemption of state AI laws that impose undue burdens, while the Act provides that it "shall not preempt any generally applicable law, such as a body of common law or a scheme of sectoral governance." This difference is consequential because existing regulatory frameworks, including FDA oversight of AI and machine learning-enabled medical devices, HIPAA, and state medical and health data privacy laws would remain fully operative under the Act's approach .

The FDA has already established an evolving framework for AI and machine learning-enabled medical devices, including its 2021 Action Plan and guidance on predetermined change control plans. The Act's preservation of "sectoral governance schemes" means FDA's existing authority over software as a medical device and clinical decision support software would remain intact, but the Act's products liability and bias audit provisions would create a multi-track compliance environment requiring organizations to navigate both federal and sectoral rules simultaneously .

Health care and life sciences are among the highest-stakes sectors for AI deployment, which is precisely why these regulatory developments demand immediate attention. The convergence of executive policy guidance and draft legislation signals that federal AI regulation may no longer be a question of "if" but "when." Organizations should begin assessing how these proposals may reshape their governance programs, compliance obligations, and product development strategies now and consider legislative engagement to ensure that patient safety protections are explicitly carved out from any preemption provision .